Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 crawled time : 19:00 save search
Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis
Published: 2023-11-27 (Crawled : 19:00) - biospace.com/
ACAD | $17.07 -0.7% -0.64% 990K
|
Health Technology
|
| O: -0.45%
H: 0.41%
C: -0.32%
acp-204 disease alzheimer’s treatment pharmaceuticals trial phase 2
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
Published: 2023-02-10 (Crawled : 19:00) - biospace.com/
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: -0.3%
H: 0.1%
C: -2.15%
incb5470 results study phase 2
Spiral winds up for phase 2 sustained-release steroid trial with $8M … – FiercePharma
Published: 2023-01-10 (Crawled : 19:00) - spacfeed.com
ENVX S | $6.01 -9.35% -10.32% 13M
|
|
| O: -0.12%
H: 4.15%
C: 2.89%
trial phase 2
Teck Secures 100% Clean Power with AES Andes for Quebrada Blanca Phase 2
Published: 2022-11-10 (Crawled : 19:00) - globenewswire.com
AES P | $16.27 0.81% -0.55% 4.8M
|
Utilities
|
| O: 0.32%
H: 0.92%
C: -0.81%
TECK | $47.72 1.1% -1.38% 2.9M
|
Non-Energy Minerals
|
| O: 3.64%
H: 3.46%
C: -1.52%
phase 2
Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference
Published: 2022-08-03 (Crawled : 19:00) - biospace.com/
AGNPF | $0.0708 5.36% 178.69% 1.3K
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -4.93%
conference study phase 2
Algernon Announces Patients Requested Ongoing Supply of Ifenprodil after IPF and Chronic Cough Phase 2 Study Ended
Published: 2022-06-21 (Crawled : 19:00) - biospace.com/
AGNPF | $0.0708 5.36% 178.69% 1.3K
|
Health Technology
|
| O: 2.48%
H: 0.0%
C: -6.35%
ongoing phase 2
I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
Published: 2022-05-19 (Crawled : 19:00) - biospace.com/
IMAB | $1.8 -0.55% -0.84% 140K
|
Health Technology
|
| O: -0.66%
H: 5.72%
C: 1.84%
cd73 report antibody phase 2
Imago BioSciences Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocythemia
Published: 2022-05-03 (Crawled : 19:00) - biospace.com/
IMGO | $36.01 0.03% 0.0% 0
|
Health Technology
|
| O: -0.3%
H: 4.07%
C: -4.72%
enroll phase 2
Xenon Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial to Evaluate XEN1101 as a Treatment for Major Depressive Disorder (MDD)
Published: 2022-05-03 (Crawled : 19:00) - biospace.com/
XENE | $40.31 -3.17% -3.15% 320K
|
Health Technology
|
| O: -0.22%
H: 0.0%
C: 0.0%
xen1101 treatment trial phase 2 major depressive disorder
Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual Meeting
Published: 2022-04-08 (Crawled : 19:00) - biospace.com/
CRDF | $4.37 -2.89% -3.33% 810K
|
Health Services
|
| O: -0.84%
H: 4.68%
C: -1.7%
trial cancer biomarkers phase 2 prostate cancer
Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with Novel, Broad-Spectrum, Orally Administrated Antiviral CC-42344
Published: 2022-03-10 (Crawled : 19:00) - biospace.com/
COCP | $1.495 4.55% -1.39% 5.1K
|
Health Technology
|
| O: 0.66%
H: 2.18%
C: -1.72%
cc-4234 phase 1 antiviral influenza cc-42344 enroll phase 2
Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb
Published: 2022-03-01 (Crawled : 19:00) - biospace.com/
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: -0.8%
H: 1.31%
C: 0.75%
il-12 program therapeutics immunotherapy one phase 1 therapy phase 2 milestone
Ayala Pharmaceuticals Announces Completion of Enrollment in Part A of RINGSIDE, a Pivotal Phase 2/3 Study of AL102 in Desmoid TumorsInterim Results expected mid-2022
Published: 2022-02-23 (Crawled : 19:00) - biospace.com/
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: -4.52%
H: 7.35%
C: -4.98%
al102 phase 2 als phase 2/3 enroll
Armata Pharmaceuticals Announces Clearance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of AP-PA02 in Non-Cystic Fibrosis Bronchiectasis
Published: 2022-02-22 (Crawled : 19:00) - biospace.com/
ARMP | $2.55 2.0% 0.0% 31K
|
Health Technology
|
| O: -0.2%
H: 6.55%
C: 1.6%
pa02 new drug phase 2 als clearance fibrosis application drug trial cystic fibrosis
Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients
Published: 2022-02-08 (Crawled : 19:00) - biospace.com/
AKRO | $20.51 -5.05% -5.19% 560K
|
Health Technology
|
| O: 0.11%
H: 1.01%
C: 0.37%
phase 2 phase 2b therapeutics nash enroll
AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022
Published: 2022-01-27 (Crawled : 19:00) - biospace.com/
AVRO | $1.24 1.64% 0.81% 37K
|
Health Technology
|
| O: 1.09%
H: 4.3%
C: -6.45%
symposium trial phase 1 phase 2 phase 3
Revelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99 for the Prevention of H3N2 Influenza InfectionTop-line data anticipated in the second quarter of 2022
Published: 2022-01-20 (Crawled : 19:00) - biospace.com/
REVB | $2.24 4.19% 10.75% 97K
|
|
| O: -9.47%
H: 7.3%
C: -9.98%
phase 2 top-line data phase 2b bioscience infection influenza group
Sorrento Begins Enrollment in Phase 2 Trial of Resiniferatoxin (RTX) for the Treatment of Pain Due to Knee Osteoarthritis (OA)
Published: 2021-12-07 (Crawled : 19:00) - globenewswire.com
SRNE | $0.024 -14.29% -8.85% 57K
|
Health Technology
|
| O: -1.68%
H: 9.4%
C: 7.52%
treatment phase 2 xin osteoarthritis trial enroll
Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection
Published: 2021-11-15 (Crawled : 19:00) - biospace.com/
JNJ | News | $145.74 0.67% -0.18% 7M
|
Health Technology
|
| O: -1.36%
H: 0.0%
C: 0.0%
ARWR | $22.61 0.36% 0.4% 1.3M
|
Health Technology
|
| O: -3.29%
H: 0.86%
C: -10.19%
phase 2 hepatitis phase 2b injection infections chronic hepatitis b
Alector Presents Encouraging New AL001 Data from the Symptomatic FTD-GRN Cohort of INFRONT-2 Phase 2 Open-label Clinical Study
Published: 2021-11-12 (Crawled : 19:00) - globenewswire.com
ALEC | $5.09 0.39% 0.59% 410K
|
Health Technology
| Email alert
Add to watchlist
phase 2 ftd-grn al001
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.